TP、NP以及GP方案治疗三阴性乳腺癌的临床疗效对比研究  

Comparative Study of Clinical Efficacy of TP,NP and GP Regimen in the Treatment of Three Negative Breast Cancer

作　　者：周广磊[1] 孙甲甲[1] 陈立明[1] 黄景昊 ZHOU Guanglei;SUN Jiajia;CHEN Liming(Affiliated Hospital of Logistics University of PAP,Tianjin,300162)

机构地区：[1]武警后勤学院附属医院,300162

出　　处：《实用癌症杂志》2018年第12期1956-1959,共4页The Practical Journal of Cancer

摘　　要：目的比较长春瑞滨联合顺铂(NP),紫杉醇联合顺铂(TP),吉他西滨联合顺铂(GP)的临床疗效。方法回顾性分析110例晚期三阴性乳腺癌患者的临床资料,按照患者接受的化疗方式不同分为NP组、TP组以及GP组。比较分析3组患者的临床疗效、中位生存时间(TTP),1年生存率,生活质量评分、疼痛评分以及不良反应。结果 NP组、TP组以及GP组患者的客观有效率分别为44. 44%,50. 00%以及50. 00%;临床有效率分别为77. 77%,78. 95%以及88. 89%。NP组、TP组以及GP组患者的中位生存时间分别为8. 2(3. 6～16. 5)月,6. 5(2. 9～16. 7)月,7. 9(3. 8～15. 4)月; 1年生存率分别为72. 22%,65. 79%,77. 78%。NP组、TP组以及GP组患者的QOL评分分别为(52. 6±4. 2)分,(53. 4±5. 61)分和(56. 5±5. 54)分; VAS评分分别为(5. 96±0. 79)分,(5. 21±0. 89)分以及(5. 15±0. 86)分。NP组、TP组以及GP组患者的不良反应发生均主要表现为骨髓抑制、胃肠道反应以及贫血。上述指标在3组之间均无统计学差异(P> 0. 05)。结论 TP、NP以及GP方案治疗三阴性乳腺癌均具有较好的临床疗效,3种方案的疗效以及不良反应方面均无统计学差异。Objective Comparison of the clinical efficacy of Changchun vinorelbine combined with cisplatin(NP),paclitaxel and cisplatin(TP),guitar and vinorelbine combined with cisplatin(GP).Methods Retrospectively analyzed the clinical data of patients with advanced triple negative breast cancer treated in our hospital from January 2014 to December 2016.The patients were divided into NP group,TP group and GP group according to the different ways of chemotherapy.The clinical efficacy,median survival time(TTP),one year survival rate,quality of life score,pain score and adverse reactions were compared and analyzed among the three groups.Results The objective response rate for the NP group,TP group and GP group were 44.44%,50.00%and 50.00%,respectively;the clinical efficiency for the three groups were 77.77%,78.95%and 88.89%,respectively.The TTP for the NP group,TP group,in group GP were 8.2(3.6~16.5),6.5(2.9~16.7),7.9(3.8~15.4),respectively.The one year survival rate for the three groups were 72.22%,65.79%and 77.78%among the three groups.The QOL score for the NP group,TP group and GP group were(52.6±4.2),(53.4±5.61)and(56.5±5.54),respectively and the VAS scores were(5.96±0.79),(5.21±0.89)and(5.15±0.86),respectively.The adverse reactions in group NP,group TP and group GP mainly showed as myelosuppression,gastrointestinal reaction and anemia.There was no significant difference in the above indexes between the three 3 groups(P>0.05).Conclusion TP,NP and GP regimens have good clinical efficacy in the treatment of triple negative breast cancer.There is no significant difference in the efficacy and adverse reactions among the three regimens.

关 键 词：三阴性乳腺癌 长春瑞滨 紫杉醇 吉西他滨 顺铂 

分 类 号：R737.9[医药卫生—肿瘤]